Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Voriconazole

FDA-approved product (tablet, oral), marketed as Vfend, Voriconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Voriconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Bacterial Infections and Mycoses
  • Candidemia
  • Candidiasis
  • Fungal infectious disease
  • Fusariosis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC03; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Voriconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Voriconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Mycotic Ulcer Treatment Trial I

    NCT00996736 · start 2010-04

    Registered record
    Registry ID
    NCT00996736
    Conditions
    Corneal Ulcer; Eye Infections, Fungal
    Interventions
    Natamycin; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2012-07
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer; Eye Infections, Fungal
    InterventionNatamycin; Voriconazole
    PhasePhase 3
    Registry statusCompleted

  • Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

    NCT00833482 · start 2009-09

    Registered record
    Registry ID
    NCT00833482
    Conditions
    Human Immunodeficiency Virus Type 1 (HIV-1); HIV Infections
    Interventions
    Voriconazole; Atazanavir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-09
    Completion
    2011-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Type 1 (HIV-1); HIV Infections
    InterventionVoriconazole; Atazanavir; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetic And Safety Study Of Voriconazole In Healthy Male And Female Adults

    NCT00855101 · start 2009-04

    Registered record
    Registry ID
    NCT00855101
    Conditions
    Healthy Volunteers
    Interventions
    voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-07
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventionvoriconazole
    PhasePhase 1
    Registry statusCompleted

  • Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

    NCT00739934 · start 2008-12

    Registered record
    Registry ID
    NCT00739934
    Conditions
    Candidiasis; Candidemia
    Interventions
    voriconazole (Vfend)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis; Candidemia
    Interventionvoriconazole (Vfend)
    PhasePhase 2
    Registry statusCompleted

  • Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease

    NCT00792246 · start 2008-12

    Registered record
    Registry ID
    NCT00792246
    Conditions
    Graft Versus Host Disease; Stem Cell Transplantation
    Interventions
    voriconazole; voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-12
    Completion
    2012-07
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft Versus Host Disease; Stem Cell Transplantation
    Interventionvoriconazole; voriconazole
    PhasePhase 1
    Registry statusCompleted

  • TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

    NCT00740389 · start 2008-09

    Registered record
    Registry ID
    NCT00740389
    Conditions
    HIV; AIDS; Fungal Infection
    Interventions
    TMC125
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2009-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Fungal Infection
    InterventionTMC125
    PhasePhase 1
    Registry statusCompleted

  • A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

    NCT00940017 · start 2008-09

    Registered record
    Registry ID
    NCT00940017
    Conditions
    Aspergillosis; Candidemia
    Interventions
    anidulafungin and voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis; Candidemia
    Interventionanidulafungin and voriconazole
    PhasePhase 4
    Registry statusCompleted

  • Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

    NCT00689338 · start 2008-07

    Registered record
    Registry ID
    NCT00689338
    Conditions
    Invasive Candidiasis
    Interventions
    Anidulafungin; Fluconazole; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2010-05
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis
    InterventionAnidulafungin; Fluconazole; Voriconazole
    PhasePhase 3
    Registry statusCompleted

  • A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

    NCT00556998 · start 2008-06

    Registered record
    Registry ID
    NCT00556998
    Conditions
    Pharmacokinetics
    Interventions
    Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2009-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    InterventionVoriconazole
    PhasePhase 2
    Registry statusCompleted

  • Antifungal Prophylaxis in Pediatric Acute Leukemia

    NCT00624143 · start 2008-02

    Registered record
    Registry ID
    NCT00624143
    Conditions
    Pediatric Acute Leukemia Induction
    Interventions
    ORAL VORICONAZOLE and IV Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Acute Leukemia Induction
    InterventionORAL VORICONAZOLE and IV Amphotericin B
    PhasePhase 3
    Registry statusUnknown

  • An Observational Analysis of Voriconazole Therapeutic Drug Concentration Monitoring, Pharmacogenomics and Clinical Outcome Correlations in High-risk Hematology Patients

    NCT01321372 · start 2007-06

    Registered record
    Registry ID
    NCT01321372
    Conditions
    Acute Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-06
    Completion
    2011-06
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection

    NCT01137292 · start 2007-04

    Registered record
    Registry ID
    NCT01137292
    Conditions
    Invasive Fungal Infections
    Interventions
    voriconazole (VFEND®)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-04
    Completion
    2009-11
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections
    Interventionvoriconazole (VFEND®)
    PhaseNot recorded
    Registry statusCompleted

  • Bioavailability and Metabolism of Voriconazole in Relation to Its Modulation by the CYP2C19 Genetic Polymorphism

    NCT00175994 · start 2005-07

    Registered record
    Registry ID
    NCT00175994
    Conditions
    Healthy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-07
    Completion
    2006-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

    NCT00150319 · start 2005-06

    Registered record
    Registry ID
    NCT00150319
    Conditions
    Kidney Failure
    Interventions
    Vfend®; I.V.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2005-06
    Completion
    2005-10
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Failure
    InterventionVfend®; I.V.
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

    NCT00177827 · start 2004-03

    Registered record
    Registry ID
    NCT00177827
    Conditions
    Post Lung Transplantation
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-03
    Completion
    2006-03
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Lung Transplantation
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted